Lifestyle Modification and Liraglutide

NCT02911818 on ClinicalTrials.gov · last registry update 2019-05-07

An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. The sponsor logged completion for November 2018. Primary outcome, as filed: Percent Change in Baseline Weight. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Pennsylvania
Sponsor type: Other
Enrollment: 150
Started: 2016-09
Primary completion: 2018-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change in Baseline Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.